Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$133.36

(0.00%)

12:52
04/19/18
04/19
12:52
04/19/18
12:52

GW Pharmaceuticals announces FDA advisors' backing for approval of cannabidiol

GW Pharmaceuticals, along with its U.S. subsidiary Greenwich Biosciences, announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration unanimously recommended supporting the approval of the New Drug Application for the investigational cannabidiol oral solution, also known as Epidiolex, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older. If approved, Epidiolex would be the first pharmaceutical formulation of purified, plant-based CBD, a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs. LGS and Dravet syndrome, which develop in childhood, are devastating forms of epilepsy with high morbidity and mortality rates and a significant burden on families and caregivers. More than 90% of patients with LGS or Dravet syndrome have multiple seizures per day, which puts them at constant risk for falls and injury. Physicians who treat LGS and Dravet syndrome patients struggle to reduce the sheer volume of dangerous seizures with currently available therapies. If approved, Epidiolex would be the first-ever FDA-approved medicine for Dravet syndrome patients. "We are pleased by the Advisory Committee's unanimous recommendation to approve Epidiolex, which would provide an important treatment option for patients with LGS and Dravet syndrome, two of the most severe and treatment-resistant forms of epilepsy," said GW's CEO Justin Gover. "This favorable outcome marks an important milestone in our company's unwavering commitment to address the significant unmet need for patients with LGS and Dravet syndrome and our resolve to study Epidiolex under the highest research and manufacturing standards. We look forward to our ongoing discussions with the FDA as it continues to review the Epidiolex NDA."

  • 19

    Apr

  • 21

    May

  • 27

    Jun

GWPH GW Pharmaceuticals
$133.36

(0.00%)

01/23/18
LEER
01/23/18
NO CHANGE
Target $153
LEER
Outperform
Leerink cautiously optimistic ahead of GW Pharmaceuticals CBDV Phase 2 data
Leerink analyst Paul Matteis reiterates an Outperform rating on GW Pharmaceuticals, while lowering his price target on the shares to $153 from $154, ahead of CBDV Phase II data in partial-onset seizures in Q1. While he acknowledges that is difficult to garner conviction in the Phase 2, his analysis of pre-clinical results - compared side-by-side to cannabidiol - instills him with "cautious optimism" on the program, while he believes that the little credit priced into the stock for CBDV sets up an upside skewed risk/reward on the upcoming data readout this quarter.
02/06/18
CANT
02/06/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals price target lowered to $192 from $208 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for GW Pharmaceuticals to $192 following the company's Q1 financial results and recent equity raise. The analyst, however, believes the shares remain "significantly undervalued," based on his assessment of Epidiolex's opportunity in treating orphan pediatric epileptic conditions. He reiterates an Overweight rating on GW.
02/22/18
CANT
02/22/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals shares could recover quickly, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros believes GW Pharmaceuticals shares could recover quickly from the selloff on the negative results with GWP42006 in adult patients with focal seizures. The analyst highlights the announcement of an advisory committee hearing for Epidiolex on April 18. The "clear near-term focus" is the successful commercialization of Epidiolex for pediatric pharmacoresistant seizures upon potential approval in the second half of 2018, Piros tells investors in a research note. He keeps an Overweight rating on GW shares with a $192 price target.
04/19/18
CANT
04/19/18
NO CHANGE
Target $205
CANT
Overweight
GW Pharmaceuticals price target raised to $205 from $192 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for GW Pharmaceuticals to $205 and reiterates an Overweight rating on the shares after an FDA advisory committee voted 13-0 that the benefit-risk profile of cannabidiol is favorable for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older.

TODAY'S FREE FLY STORIES

DAC

Danaos

$1.60

0.05 (3.23%)

16:52
09/24/18
09/24
16:52
09/24/18
16:52
Earnings
Danaos reports Q2 EPS 27c, one estimate 23c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AWK

American Water

$87.80

-0.8 (-0.90%)

16:46
09/24/18
09/24
16:46
09/24/18
16:46
Hot Stocks
American Water to spend $2M to upgrade water main in Missouri »

Missouri American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

COLD

Americold Realty Trust

$25.25

-0.09 (-0.36%)

16:45
09/24/18
09/24
16:45
09/24/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Americold Realty Trust »

Senator Investment Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRNB

Principia Biopharma

$27.34

0.24 (0.89%)

16:45
09/24/18
09/24
16:45
09/24/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Principia Biopharma »

Cormorant Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DCPH

Deciphera

$39.80

0.78 (2.00%)

16:42
09/24/18
09/24
16:42
09/24/18
16:42
Initiation
Deciphera initiated  »

Deciphera initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 27

    Nov

BJ

BJ's Wholesale

$28.47

-0.68 (-2.33%)

16:42
09/24/18
09/24
16:42
09/24/18
16:42
Syndicate
BJ's Wholesale files to sell 28M shares of common stock for holders »

BofA Merrill Lynch,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

BPMC

Blueprint Medicines

$71.56

1.8 (2.58%)

16:41
09/24/18
09/24
16:41
09/24/18
16:41
Initiation
Blueprint Medicines initiated  »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGEN

Seattle Genetics

$78.57

0.53 (0.68%)

16:41
09/24/18
09/24
16:41
09/24/18
16:41
Initiation
Seattle Genetics initiated  »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOXO

Loxo Oncology

$163.07

3.91 (2.46%)

16:40
09/24/18
09/24
16:40
09/24/18
16:40
Initiation
Loxo Oncology initiated  »

Loxo Oncology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

INCY

Incyte

$66.48

-0.11 (-0.17%)

16:40
09/24/18
09/24
16:40
09/24/18
16:40
Initiation
Incyte initiated  »

Incyte initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AGIO

Agios Pharmaceuticals

$75.39

1.84 (2.50%)

16:40
09/24/18
09/24
16:40
09/24/18
16:40
Initiation
Agios Pharmaceuticals initiated  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMLR

Semler Scientific

$0.00

(0.00%)

16:40
09/24/18
09/24
16:40
09/24/18
16:40
Hot Stocks
Breaking Hot Stocks news story on Semler Scientific »

Park West Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$32.63

0.22 (0.68%)

16:39
09/24/18
09/24
16:39
09/24/18
16:39
Initiation
Clovis initiated  »

Clovis initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.09

-0.94 (-0.32%)

16:39
09/24/18
09/24
16:39
09/24/18
16:39
Periodicals
Trump inks revised trade pact with South Korea, CNBC says »

U.S. president Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.09

-0.94 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$36.41

-1.27 (-3.37%)

16:39
09/24/18
09/24
16:39
09/24/18
16:39
Initiation
Tesaro initiated  »

Tesaro initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

BGNE

BeiGene

$166.12

2.15 (1.31%)

16:38
09/24/18
09/24
16:38
09/24/18
16:38
Initiation
BeiGene initiated  »

BeiGene initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 27

    Nov

BW

Babcock & Wilcox

$1.03

0.005 (0.49%)

16:38
09/24/18
09/24
16:38
09/24/18
16:38
Hot Stocks
Babcock & Wilcox to relocate Headquarters to Ohio »

Babcock & Wilcox…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.63

-0.022 (-3.37%)

16:37
09/24/18
09/24
16:37
09/24/18
16:37
Hot Stocks
Jaguar Health, Knight Therapeutics announce strategic partnership »

Knight Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HST

Host Hotels

$20.89

-0.23 (-1.09%)

, VNO

Vornado

$73.52

-1.58 (-2.10%)

16:36
09/24/18
09/24
16:36
09/24/18
16:36
Hot Stocks
Host Hotels sells New York Marriott Marquis Retail to Vornado for $442M »

Host Hotels & Resorts…

HST

Host Hotels

$20.89

-0.23 (-1.09%)

VNO

Vornado

$73.52

-1.58 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CWEN

Clearway Energy

$19.85

-0.1 (-0.50%)

16:33
09/24/18
09/24
16:33
09/24/18
16:33
Syndicate
Clearway Energy announces offering of 3.92M shares of Class C common stock »

Clearway Energy …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KIRK

Kirkland's

$9.30

-0.02 (-0.21%)

16:33
09/24/18
09/24
16:33
09/24/18
16:33
Hot Stocks
Kirkland's announces new $10M share repurchase program »

Kirkland's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$18.76

-0.285 (-1.50%)

16:32
09/24/18
09/24
16:32
09/24/18
16:32
Hot Stocks
Summit Materials sells GJP to Ferguson Waterworks, terms not stated »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KIRK

Kirkland's

$9.30

-0.02 (-0.21%)

16:32
09/24/18
09/24
16:32
09/24/18
16:32
Hot Stocks
Kirkland's names Steve Woodward as CEO, Mike Cairnes as COO »

Kirkland's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRE

Washington REIT

$30.60

-0.32 (-1.03%)

16:32
09/24/18
09/24
16:32
09/24/18
16:32
Periodicals
Washington REIT explores sale of retail portfolio, Bloomberg reports »

Washington REIT is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.09

-0.94 (-0.32%)

16:31
09/24/18
09/24
16:31
09/24/18
16:31
Periodicals
Trump says second meeting with Kim Jong Un likely 'quite soon,' AP says »

U.S. president Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.09

-0.94 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.